Summary
Background. Curative resection of pancreatic adenocarcinoma is the only clinical parameter related to a favorable prognosis while other clinicopathological parameters fail. To evaluate whether angiogenesis, vascular endothelial growth factor (VEGF) or certain tumor proteases, e.g., cathepsin B (CTSB) and L (CTSL), are factors of prognostic relevance, we investigated their expression in patients with long- and short-term survival after curative resection (R0) because of pancreatic adenocarcinoma.
Methods. Twenty-nine tissue samples from patients with adenocarcinoma of the pancreas were examined. The patients were selected in a long-term survival group with a survival ≥24 mo (n=18) and a short-term survival group of patients, who died within 8 mo after surgery because of their malignancy (n=11). The microvessel quantification was performed immunohistochemically using a monoclonal anti-CD34 antibody. VEGF, CTSB, and CTSL expressions was studied using polyclonal antibodies (PAbs).
Results. The median microvessel density (MVD) was 75 (range 39–182). MVD correlated significantly with the survival time after surgery (p=0.0132) but not with clinicopathological parameters. In cancer cells, VEGF was positive in 82.8% and showed significant correlation with the MVD (p=0.0002) and survival time (p=0.0395). Positive immunoreactivity could be obtained for 96.5% for CTSB and 84.2% for CTSL. Expression of both proteases correlated significantly with the survival time after surgery (CTSB p=0.0002, CTSL p=0.0001). Furthermore, CTSB expression correlated with invasion of the perineural space. Thus, a short postoperative survival correlated with a high MVD, and highly expressed VEGF, CTSB, and CTSL. No significant correlation between MVD, VEGF, as well as CTSL and clinicopathological parameters was found. For routinely assessed markers (e.g., TNM-stage, UICC-stage, and so on) no significant correlation with survival time was found in this small group of patients.
Conclusion. These findings indicate that the MVD, VEGF, CTSB, and CTSL are prognostic factors after curative resection, whereas other parameters (TNM, UICC, and so on) failed to show prognostic relevance in our group of patients. Furthermore, the correlation between MVD and VEGF underlines the importance of this growth factor for angiogenesis and tumor growth. The correlation between CTSB and perineural invasion demonstrates the involvement of cathepsins in local tumor invasion.
Similar content being viewed by others
References
Warshaw AL, del Castillo F. Pancreatic carcinoma. N Engl J Med 1992; 326: 455.
Trede M, Schwall G, Saeger HD. Survival after pancreaticoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447–458.
Trede M. Surgical Options for Pancreatic Cancer, in Surgery of the Pancreas, Trede M, Carter DC, eds. Churchill Livingston, New York, NY, 1997, pp. 471–481.
Yeo CJ, Cameron JL. Prognostic factors in ductal pan creatic cancer. Langenbecks Arch Surg 1998; 383: 129–133.
Ellenrieder V, Adler G, Gress TM. Invasion and metastasis in pancreatic cancer. Ann Oncol 1999; 10(suppl) 46–50.
Lemoine NR. Molecular advances in pancreatic cancer. Digestion 1997; 58: 550–556.
Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58–61.
Weidner N, Semple JP, Welch WR, Folkman N. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8.
Maeda K, Chung YS, Takatuka S, Ogawa Y, Onoda N, Sawada T, et al. Tumor angiogenesis and tumor cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995; 72: 319–323.
Ferrara N, Houck KA, Jakeman L, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211–218.
Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastases. Clin Exp Met 1992; 10: 145–155.
Kuliawat R, Klumperman J, Ludwig T, Arvan P. Differential sorting of lysosomal enzymes out of the regulated secretory pathway in pancreatic β-cells. J Cell Biol 1997; 137: 595–608.
Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Carroccio A, et al. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas 1997; 14: 22–27.
Ohta T, Terada T, Nagakawa T. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesion. Br J Cancer 1994; 69: 152–156.
Yamaguchi N, Chung SM, Shiroeda O, Imanishi J. Characterization of a cathepsin L-like enzyme secreted from human pancreatic cancer cell line HPC-YP. Cancer Res. 1990; 50: 658–663.
Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322: 297–302.
Breslow NE. Analysis of survival data under the proportional hazards model. Int. Stat Rev. 1975; 43: 45–58.
Wilcoxon F, Katti SK, Wilcox RA. Critical values and probability levels for the Wilcoxon Rank Sum Test and the Wilcoxon signed rank test. Pearl River, NY, Lederle Laboratories, 1963.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457,458.
Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170.
Dugan MC and Sarkar FH. Current concepts in pancreatic cancer: symposium summary. Pancreas 1998; 17: 325–333.
Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111–115.
Fidler IJ and Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastases. Cell 1994; 79: 185–188.
Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029–1039.
Kuehn R, Lelkes PI, Bloechle C, Niendorf A, Izbicki JR. Angiogenesis, angiogenic growth factors, and cell adhesion molecules are upregulated in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas 1999; 18: 96–103.
Boehle AS, Kalthoff H. Molecular mechanisms of tumor metastasis and angiogenesis. Langenbecks Arch Surg 1999; 384: 133–140.
Siemeister G, Martiny-Baron G, Marme D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metastasis Rev 1998; 17: 241–248.
Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, Isner JM. Hypoxia-induced paracrine regulation of vascular endothelian growth factor. J Clin Invest 1996; 97: 469–476.
Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirawasa S, Sasa zuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55: 4575–4580.
Detmar M, Brown LF, Claffey KB, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141–1146.
Ikeda N, Adachi M, Taki T, Hashida H, Sho M, Nakajima Y, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999; 79: 1553–1563.
Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–1763.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS. Inhibition of vascular endothelial growth factor-induced angiogenesis supresses tumor growth in vivo. Nature 1993; 362: 4262–4267.
O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M. Angiostatin: a novel angiogenesis inhibitor that mediates the supression of metatases by a Lewis lung carcinoma. Cell 1994; 79: 315–328.
Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56:1324–1330.
Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, et al. Expression of two angiogenic factors, VEGF and PDEGF in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1989; 34:1439–1447.
Sloane BF, Dunn JR, Honn KV. Lysosomal Cathepsin B: correlation with metastatic potential. Science 1981; 212:1151–1153.
Im B, Kominami E, Grube D, Uchiyama Y. Immunhistocytocemical localization of cathepsin B and H in human pancreatic endocrinecells and insulinoma cells. Histochem 1998; 93: 111–118.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Niedergethmann, M., Hildenbrand, R., Wolf, G. et al. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. International Journal of Pancreatology 28, 31–39 (2000). https://doi.org/10.1385/IJGC:28:1:31
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/IJGC:28:1:31